<DOC>
	<DOCNO>NCT00760110</DOCNO>
	<brief_summary>Previous cross-sectional study demonstrate blood pressure ( BP ) measurements home ( HBP ) morning offer strong predictive power micro- macrovascular complication patient type 1 2 diabetes casual/clinic blood pressure measurement ( CBP ) . The present study examine HBP CBP provide strong predictive power outcome compare cumulative event hypertensive normotensive patient 6 year prospective , longitudinal study patient type 2 diabetes .</brief_summary>
	<brief_title>A Cohort Study Morning Home Blood Pressure Measurement Type 2 Diabetic Patients</brief_title>
	<detailed_description>RESEARCH DESIGN AND METHODS １.Subjects . After detailed baseline examination , 400 Japanese subject follow all-cause mortality morbidity . All participant visit clinic regularly . Mean survey duration patient 42.1±20.0 month ( range , 3-72 month ) .Type 2 diabetes diagnose accord World Health Organization criteria.At begin study , 329 patient ( 82 % ) receiving treatment oral hypoglycemic drug and/or insulin regimen diabetes mellitus 196 patient ( 49 % ) receive treatment various anti-hypertensive drug ( angiotensin-converting enzyme inhibitor , angiotensin receptor blocker , calcium channel blocker others ) hypertension . Mean disease duration 13±8 year ( range , 0-40 year ) . Mean value baseline measurement follow : BMI,23.7±3.4 kg/m2 ; HbA1c,6.7±1.1 % ; triglycerides,150±112 mg/dl ; total cholesterol,198±32 mg/dl ; LDL,110±29 mg/dl ; HDL,60±19 mg/dl.All patient fully inform purpose procedure study provide oral consent enrolment . 2 . Baseline follow-up assessment . Participants examine use method report previously ( 1,2 ) . Briefly , chemical laboratory data obtain visit without fast morning . BP measure clinic home wake morning . Clinic hypertension ( CH ) morning hypertension ( MH ) define systolic BP ( SBP ) &gt; =130 mmHg and/or diastolic BP ( DBP ) &gt; =85 mmHg , clinic normotension ( CN ) morning normotension ( MN ) define SBP &lt; 130 mmHg DBP &lt; 86 mmHg , respectively . Microalbuminuria clinical albuminuria define urinary albumin excretion rate &gt; =30 mg/g creatinine &gt; =300 mg/g creatinine , respectively . Microvascular complication check baseline every 3 6 month throughout study . Severity nephropathy determine use 4 category : normal ; microalbuminuria ; clinical albuminuria ; dialysis . Severity retinopathy categorize : normal ; non-proliferative retinopathy ; pre-proliferative retinopathy ; proliferative retinopathy . Development change microvascular event define accord change least 1 step baseline ( 3,4 ) . Macrovascular complication coronary heart disease ( CHD ) cerebrovascular disease ( CVD ) . These event confirm medical history , include content treatment . New worsen ( recurrent ) event define base clinical manifestation treatment throughout study . At baseline , HT NTs determine basis HBP CBP measurement . Based HBP , subject divide MH MN patient , endpoint determine within survey duration , define patient display sustenance BP status . That , survey duration vary individual patient defined period time MH patient baseline display change MN , MN patient baseline display change MH . Mean survey duration endpoints 29.5±21.1 month ( range , 3-72 month ) . Also , base CBP , subject divide CH CN patient . These patient follow use method use MH MN . Mean survey duration endpoints 34.9±22.3 month ( range,3-72 month ) , significantly longer base HBP ( P &lt; 0.001 ) . For ethical reason , patient treat various anti-hypertensive , anti-diabetic , anti-dyslipidemia and/or anti-hypercoagulation agent course study patients'own doctor part continue standard medical care . 3 . Study endpoints outcome measure . The primary endpoint death cause . Secondary endpoint new , worsen improved microvascular event new worsen macrovascular event . 4 . Statistical analysis 1 . Baseline . Mean value compare use Student 's pair unpaired test . To compare prevalence micro- macrovascular complication medical treatment patient without hypertension basis HBP CBP , Fischer 's exact test two-tailed P value use , odds ratio 95 % confidence interval ( CI ) calculate . If prevalence event zero , 0.5 add value calculate odds ratio 95 % CI . 2 . Endpoints outcome measure . Differences outcomes endpoint death new worsen micro- macrovascular complication sustain hypertensive normotensive patient basis HBP CBP assess use survival curve calculate accord Kaplan-Meier method , compare hazard ratio use log-rank test . Within survey time define , time censor death ( occurrence event ) calculate endpoint . 3 . Risk factor assessment outcome . Risk factor relate outcome determine statistically log-rank test assess use hazard ratio Cox proportional hazard model . For outcome microvascular complication , risk factor determine new , worsen improved event . Omnibus test use determine appropriateness Cox proportional hazard model . Confounding factor use analysis variable MH CH baseline additional therapy disease . Analysis perform use Prism version 5.01 software ( GraphPad Software , CA , USA ) Dr. SPSSII Windows ( SPSS Japan , Tokyo , Japan ) . Two-tailed value P &lt; 0.05 define statistically significant . References 1 . Kamoi K , et al . Usefulness home blood pressure measurement morning type 2 diabetic patient . Diabetes Care 25:2218-2223 , 2002 2 . Kamoi K , et al.Usefulness home blood pressure measurement morning type 1 diabetic patient . Diabetes Care 26:2218-2223 , 2003 3 . The Diabetes Control Complications Trial Research Group : The effect intensive treatment diabetes development progression long-term complication insulin-dependent diabetes mellitus . N Engl J Med 329:977-986 , 1993 4 . Ohkubo Y , et al Intensive insulin therapy prevent progression diabetic microvascular complication Japanese patient non-insulin-dependent diabetes mellitus : randomize prospective 6-year study . Diabetes Res Clin Pract 28:103-117 , 1995</detailed_description>
	<criteria>Type 2 diabetic patient HBP CBP measurement Type 1 2 diabetic patient without HBP CBP measurement</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>87 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Morning BP</keyword>
	<keyword>Clinic BP</keyword>
	<keyword>micro- macrovascular complication</keyword>
</DOC>